Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

PHASE2UnknownINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2018

Study Completion Date

December 31, 2019

Conditions
Metastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal
Interventions
DRUG

Fulvestrant plus Goserelin

Fulvestrant s.c. plus Goserelin s.c.

DRUG

Anastrozole plus Goserelin

Anastrozole 1 mg p.o. plus Goserelin s.c.

DRUG

Goserelin

Goserelin s.c.

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Ulsan University Hospital

OTHER

collaborator

Kosin University Gospel Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Korea University Anam Hospital

OTHER

lead

Samsung Medical Center

OTHER